Skip to main content
SpringerLink
Log in

Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFα antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound–for example, in detailed comparative studies and economic analyses—is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2

Similar content being viewed by others

References

  1. Fuch BS, Hadi S. Use of etanercept in the treatment of psoriasis and psoriatic arthritis. Rev Recent Clin Trials 2006; 1: 259–63

    Article  Google Scholar 

  2. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007; 8: 143–55

    Article  PubMed  Google Scholar 

  3. National Psoriasis Foundation. About psoriatic arthritis. [cited 2008 30 December]; Available from: http://www.psoriasis.org/about/psa

  4. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52: 1–19

    Article  PubMed  Google Scholar 

  5. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 2008; 26: 121–9

    Article  PubMed  Google Scholar 

  6. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5–21

    Article  PubMed  Google Scholar 

  7. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26 (5 Suppl. 51): S62–5

    Google Scholar 

  8. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl. 2): 2–9

    Article  PubMed  CAS  Google Scholar 

  9. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8: 355–63

    Article  PubMed  CAS  Google Scholar 

  10. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868–72

    CAS  Google Scholar 

  11. Lebwohl MG. Use of etanercept in the dermatology setting. A review. Am J Clin Dermatol 2005; 6: 49–59

    Google Scholar 

  12. Warren RB, Brown BC, Griffiths CE. Topical treatments for scalp psoriasis. Drugs 2008; 68: 2293–302

    Article  PubMed  CAS  Google Scholar 

  13. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197–204

    Article  PubMed  Google Scholar 

  14. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826–50

    Google Scholar 

  15. Gottlieb A, Korman NJ, Gordon KB, et al.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851–64

    Google Scholar 

  16. European Medicines Authority. Etanercept (Enbrel®): summary of product characteristics. [cited 2008 30 December]; Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-PI-en.pdf

  17. Food and Drug Administration. Etanercept (Enbrel®): product information. 2008 [cited 2008 30 December]; Available from: http://www.fda.gov/cder/foi/label/2008/103795s5359lbl.pdf

  18. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573.e1–573.e13

    Article  Google Scholar 

  19. Sanchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006; 29: 675–85

    Article  Google Scholar 

  20. Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006; 29: 49–66

    Article  PubMed  CAS  Google Scholar 

  21. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274–85

    Article  PubMed  CAS  Google Scholar 

  22. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54 (3 Suppl. 2): S101–11

    Article  Google Scholar 

  23. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54 (3 Suppl. 2): S92–100

    Article  Google Scholar 

  24. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627–32; discussion on page 1632

    Article  PubMed  CAS  Google Scholar 

  25. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22

    Article  PubMed  CAS  Google Scholar 

  26. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241–51

    Article  PubMed  CAS  Google Scholar 

  27. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–12

    Article  PubMed  CAS  Google Scholar 

  28. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719–26

    Article  PubMed  CAS  Google Scholar 

  29. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598–603

    Article  PubMed  Google Scholar 

  30. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29–35

    Article  PubMed  CAS  Google Scholar 

  31. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264–72

    Article  PubMed  CAS  Google Scholar 

  32. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33: 712–21

    PubMed  CAS  Google Scholar 

  33. Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat 2006; 17: 343–52

    Article  PubMed  CAS  Google Scholar 

  34. Kimball AB, Jackson JM, Sobell JM, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the EDUCATE trial. J Drugs Dermatol 2007; 6: 299–306

    PubMed  Google Scholar 

Download references

Acknowledgments

Editorial assistance for the preparation of this manuscript was provided by David Murdoch and Stephanie Blick of inScience Communications. This assistance was funded by Pfizer. Dr Prodanovich reports no conflicts of interest. Dr Ricotti gave a lecture on behalf of Abbot and declares no conflicts of interest. Dr Glick is a speaker and/or has received honoraria for the following pharmaceutical companies: Amgen, Abbot, Allergan, Merck, Pharmaderm and Stiefel (Glaxo). Dr Inverardi declares no conflicts of interest. Dr Leonardi is a consultant for Abbott, Amgen, Centocor and Pfizer; he has been an investigator for Abbott, Amgen, Celgene, Centocor, Genentech, Eli Lilly, Genzyme, Pfizer, Incyte, ScheringPlough, Novartis, Novo Nordisk, Vascular Biogenics and Wyeth. Dr Leonardi is on the speakers’ bureau for Abbott, Amgen, and Centocor. Dr Kerdel has served in advisory boards, has received grants and regularly speaks for Amgen/Wyeth.

Author information

Authors and Affiliations

  1. Florida Academic Dermatology Centers, 1400 NW 12th Avenue, Miami, Florida, 33136, USA

    Srdjan Prodanovich, Carlos Ricotti, Brad P. Glick, Luca Inverardi, Craig L. Leonardi & Francisco Kerdel

Authors
  1. Srdjan Prodanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Ricotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brad P. Glick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Inverardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Craig L. Leonardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francisco Kerdel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prodanovich, S., Ricotti, C., Glick, B.P. et al. Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis. AM J Clin Dermatol 11 (Suppl 1), 3–9 (2010). https://doi.org/10.2165/1153413-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1153413-S0-000000000-00000

Keywords

Search

Navigation